Last reviewed · How we verify
Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
This combination uses an EGFR-targeting monoclonal antibody (nimotuzumab) and a PD-1 inhibitor (toripalimab) alongside chemotherapy (cisplatin and gemcitabine) to block tumor growth signaling and enhance immune-mediated cancer cell killing.
This combination uses an EGFR-targeting monoclonal antibody (nimotuzumab) and a PD-1 inhibitor (toripalimab) alongside chemotherapy (cisplatin and gemcitabine) to block tumor growth signaling and enhance immune-mediated cancer cell killing. Used for Locally advanced or metastatic squamous cell carcinoma of the head and neck, Non-small cell lung cancer (NSCLC).
At a glance
| Generic name | Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Combination therapy: EGFR inhibitor (monoclonal antibody), PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog |
| Target | EGFR (nimotuzumab), PD-1 (toripalimab), DNA (cisplatin and gemcitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nimotuzumab blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Toripalimab is a PD-1 checkpoint inhibitor that releases immune suppression, allowing T cells to attack cancer cells. Cisplatin and gemcitabine are cytotoxic chemotherapy agents that directly damage tumor DNA. Together, this quadruple regimen combines targeted therapy, immunotherapy, and chemotherapy.
Approved indications
- Locally advanced or metastatic squamous cell carcinoma of the head and neck
- Non-small cell lung cancer (NSCLC)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
- Immune-related adverse events (from toripalimab)
- Infusion reactions
Key clinical trials
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE2)
- TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma (PHASE3)
- GNT Induction Treatment in Locally Advanced NPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: